ENXTPA:VETOPharmaceuticals
Vetoquinol (ENXTPA:VETO) Stock Gains Credibility As Margins Hold Near 12%
Vetoquinol stock has quietly added double digit gains over the past three months, yet the latest move hinges on one key idea: margin credibility. H1 2026 revenue landed at €259.3 million, broadly steady, while net income reached €30.5 million. That keeps trailing net profit margin close to 12%, a rare pocket of stability in animal health where input costs can easily squeeze profitability. The market is reacting to that resilience as much as the headline earnings line, rewarding a business...